Nephrotic Syndrome Management: A Critical Review of Evidence-Based Phyto-Therapies and Clinical Integration Strategies

Nephrotic Syndrome Management: A Critical Review of Evidence-Based Phyto-Therapies and Clinical Integration Strategies

I. Clinical Foundations of Nephrotic Syndrome (NS)

1.1 Defining the Glomerular Barrier Dysfunction: NS as a Clinical Syndrome

Nephrotic Syndrome (NS) constitutes a defined clinical disorder arising from severe pathology of the renal filtration apparatus, the glomerulus. It is universally characterized by a defining clinical triad: massive proteinuria, hypoalbuminemia, and peripheral edema, often accompanied by hyperlipidemia. 

The massive loss of protein into the urine serves as the fundamental pathological mechanism, driving the cascade of subsequent physiological disturbances. This hallmark feature, proteinuria, is clinically quantified as the urinary loss of 3 grams or more of protein per 24 hours in adults, or, in pediatric populations, exceeding 40 \text{ mg/m}^2 \text{ per hour}. The consequent depletion of circulating proteins results in hypoalbuminemia, defined by serum albumin concentrations falling below 30 \text{ g/L}. 

The underlying pathophysiology is centered on a failure of selective permeability through the damaged glomerular basement membrane (GBM). The primary injury site resides within the glomeruli—the intricate clusters of small blood vessels responsible for separating necessary blood components from waste. Normally, the glomeruli retain large molecules, such as albumin, which is essential for maintaining fluid balance, while filtering wastes. When damaged, this critical barrier fails, permitting excessive blood protein to leak into the urine, thereby initiating the syndrome. 

The Pivotal Role of the Podocyte

The integrity of the renal filtration barrier is critically dependent on specialized visceral epithelial cells known as podocytes. These cells extend interdigitating foot processes (FPs) connected by the slit diaphragm (SD) complex, forming the ultimate selective barrier. In nephrotic pathology, the early events are marked by molecular alterations in the SD complex or, most frequently, a structural reorganization involving the effacement (fusion) of the FPs. This structural breakdown eliminates the filtration slits, permitting massive protein leakage. Given that podocyte malfunction is central to various proteinuric glomerular diseases, these cells represent a primary molecular target for therapeutic intervention aimed at halting the progression of chronic kidney disease (CKD). 

1.2 Etiological Spectrum and Primary Drivers

The clinical presentation of Nephrotic Syndrome can result from a spectrum of causes, ranging from diseases intrinsic to the kidney structure (primary) to manifestations of underlying systemic illness (secondary). 

Primary causes include Minimal Change Disease (MCD), most prevalent in children, and Focal Segmental Glomerulosclerosis (FSGS) and Membranous Nephropathy (MN), common histological subtypes in adults. FSGS, in particular, is highly concerning due to the difficulty in achieving sustained remission, often leading to End-Stage Renal Disease (ESRD) and frequently recurring even after a kidney transplant. Secondary NS results from conditions such as Diabetic Nephropathy (DN), Systemic Lupus Erythematosus (SLE), amyloidosis, congenital infections, or the adverse effects of certain medications. 

The heterogeneous nature of NS etiologies carries significant implications for holistic management strategies. Since the specific driver of glomerular injury varies—be it an autoimmune attack (SLE), a metabolic consequence (DN), or a primary podocytopathy (FSGS)—a universally "best" holistic agent cannot be nominated unless its action targets a common, unifying downstream pathway (e.g., inflammation or oxidative stress). Therefore, the selection process for adjunctive phyto-therapy must be fundamentally guided by the confirmed underlying pathology. The evaluation of therapeutic candidates must, consequently, scrutinize their demonstrated mechanism against the most probable or severe underlying causes of the syndrome.

1.3 Pathogenesis of Clinical Manifestations and Complications

The massive loss of protein generates systemic fluid imbalances and secondary metabolic disturbances.

Edema Formation

Edema, presenting as swelling, typically in the legs, feet, ankles, or face, is a classic symptom of NS. The development of fluid retention is classically explained by the Underfill Hypothesis, where profound hypoalbuminemia leads to a decline in plasma colloid osmotic pressure, causing increased extravasation of water into the interstitial tissues. However, an alternative, the Overfill Hypothesis, suggests that an intrinsic defect in the renal tubules contributes independently to a failure of adequate sodium excretion, leading to primary fluid retention. 

Life-Threatening Complications

Nephrotic Syndrome significantly elevates the risk profile for severe complications due to the alteration of plasma protein concentrations. 

Infections: Patients experience an elevated risk of infection, often attributed to the urinary loss of immunoglobulins and impaired immune function. 

Thromboembolism (TE): NS is a major risk factor for arterial and venous TE. Patients with massive proteinuria face a 3.4-fold higher risk of venous TE. The underlying mechanism involves the loss of natural anticoagulant factors in the urine and concomitant hepatic overproduction of pro-thrombotic factors. Managing this complication requires careful attention to potential anticoagulation prophylaxis or timely treatment of established events. 

Progression to Kidney Failure: Sustained glomerular injury invariably leads to Chronic Kidney Disease (CKD). If renal function declines critically, patients may face the need for emergency dialysis or progression to End-Stage Renal Disease (ESRD), requiring long-term renal replacement therapy or transplantation. 

 Clinical Feature (The Quadrad) Definition/Diagnostic Criteria Physiological Consequence Major Clinical Risk
Massive Proteinuria (Proteinuria) (Adults) or (Children) Loss of essential blood proteins; Driving force for other symptoms Progression of glomerular injury
Hypoalbuminemia Serum albumin Decreased plasma colloid osmotic pressure Edema, intravascular volume depletion (hypovolemia)
Edema Peripheral swelling (legs, ankles, face) Fluid retention due to reduced osmotic pressure and sodium retention Pulmonary edema, acute kidney injury (AKI)
Hyperlipidemia Elevated cholesterol and triglycerides Increased hepatic lipoprotein synthesis and altered clearance Increased cardiovascular disease risk

Table 1: Key Diagnostic Features and Associated Complications of Nephrotic Syndrome

II. Conventional Treatment Paradigms and Supportive Care

2.1 Pharmacological Cornerstones of NS Management

The therapeutic objective in NS is the induction and maintenance of remission while mitigating potential complications.

Corticosteroids, predominantly oral Prednisone or Prednisolone, are the standard initial treatment, particularly for Minimal Change Disease and some forms of Focal Segmental Glomerulosclerosis. Treatment protocols typically involve a high daily dose (e.g., or per day) until remission is achieved, followed by a prolonged alternate-day maintenance and tapering phase.

For disease refractory to steroids or those with complex secondary etiologies, management escalates to immunosuppressive agents. These include calcineurin inhibitors such as Cyclosporine or Tacrolimus, antiproliferative drugs like Mycophenolate Mofetil (MMF) or Cyclophosphamide, and biological agents like Rituximab. The specific choice is dictated by the etiology; for instance, Lupus Nephritis requires a combination of prednisone and MMF or cyclophosphamide.

Angiotensin-Converting Enzyme (ACE) inhibitors or Angiotensin Receptor Blockers (ARBs) are mandatory components of NS treatment. These agents provide renoprotection by reducing intra-glomerular pressure and decreasing proteinuria, independent of their blood pressure effects, thereby slowing the progression of kidney damage.

2.2 Essential Supportive Care and Dietary Management

Supportive care manages the profound symptoms and metabolic sequelae of NS.

Edema Control and Sodium Restriction

Control of edema requires strict fluid management and rigorous sodium restriction to counteract fluid overload and hypertension. Loop diuretics, such as Furosemide, are frequently used; however, caution is essential, as diuretics can precipitate intravascular volume depletion and acute kidney injury if not administered judiciously. Dietary counseling focuses on avoiding processed foods, which are the main source of sodium, and choosing products labeled as low-sodium (140 mg or less per serving).

Protein Intake Nuance

Managing protein consumption requires a delicate clinical balance. Although patients experience massive protein loss, excessively high protein intake is not indicated, as it increases the filtering workload on the damaged glomeruli and can potentially exacerbate proteinuria. While historically, severe protein restriction sometimes induced remission in adults, this remains anecdotal and complex. Current consensus advises moderate, carefully individualized protein intake, typically around 1 \text{ g} per kilogram of body weight per day, monitored closely in consultation with a nephrologist to balance nutritional integrity against renal workload. This nuanced approach ensures the patient receives essential protein for muscle and immune function without accelerating kidney damage.

Lipid Management

Hyperlipidemia, characterized by elevated cholesterol and triglycerides, is common and significantly increases cardiovascular risk. Dietary management involves limiting saturated fats and eliminating trans fats, favoring lean meats, poultry, and healthy oils such as olive or canola oil.

III. Comprehensive Review of Leading Adjunctive Phyto-Therapies

3.1 Criteria for Selection of the "Best" Holistic Agent

The determination of the most effective and safe holistic ingredient necessitates a rigorous, evidence-based standard based on three primary factors: (1) demonstrable clinical efficacy in human trials (reduction of 24-hour proteinuria); (2) a favorable long-term safety and toxicity profile; and (3) a plausible molecular mechanism targeting NS pathology (podocyte injury, inflammation).

3.2 Candidate 1: Astragalus membranaceus (Huangqi): The Immunomodulator and Renoprotector

Origin and Traditional Use

Astragalus membranaceus (Huangqi) is a highly valued herb in Traditional Chinese Medicine (TCM), utilized for centuries in the treatment of chronic kidney disorders and Nephrotic Syndrome. Its active components include a complex mixture of polysaccharides (APS), saponins, and flavonoids. 

Efficacy Data Synthesis (Adjunctive Use)

Clinical evidence, particularly from systematic reviews and meta-analyses, provides robust support for the use of Astragalus as an adjunct to conventional therapy. 

Proteinuria and Albumin Improvement: Astragalus combined with standard treatment significantly decreases 24-hour proteinuria, with pooled results indicating a measurable reduction of approximately -0.53 \text{ g/24 h} at the end of treatment compared to conventional therapy alone. Furthermore, supplementation is associated with a significant increase in serum albumin levels (Mean Difference of 3.24 \text{ g/L} in non-dialysis patients). 

Renal Function and Blood Pressure: Evidence suggests a positive effect on renal function, including increased creatinine clearance. Additionally, Astragalus has been shown to reduce both systolic and diastolic blood pressure in hypertensive patients. 

Immunological Support: A crucial benefit is observed in reducing the incidence of infections. Studies indicate that Astragalus granules may reduce the number of upper respiratory tract infections (URTI) in children with NS, a cohort highly susceptible to infectious complications. 

Molecular Mechanism of Action

The primary molecular mechanism of Astragalus centers on its immunomodulatory and anti-inflammatory effects. Astragalus Polysaccharides (APS) specifically protect against experimental glomerulonephritis by inhibiting the Nuclear Transcription Factor-kappaB (NF-\kappaB) mediated-cytokine pathway. NF-\kappaB is a critical regulator of inflammatory genes. Its inhibition suppresses the production of key pro-inflammatory cytokines, including Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-\alpha), and Interleukin-2 (IL-2), thereby mitigating the chronic inflammatory damage driving renal pathology. 

3.3 Candidate 2: Curcumin (Curcuma longa): The Antioxidant and Podocyte Protector

Origin and Components

Curcumin, derived from the spice turmeric, is the key curcuminoid compound, valued for its potent anti-inflammatory, antioxidant, and anti-fibrotic properties. 

Renoprotective Mechanisms

Curcumin provides therapeutic potential by addressing key upstream drivers of glomerular injury: oxidative stress and inflammation. 

Anti-oxidant and Anti-inflammatory Pathways: Curcumin protects the kidney by activating the Nrf2 pathway and inhibiting NF-\kappaB signaling, suppressing inflammation and oxidative damage. It has been shown to alleviate kidney damage in animal models by inhibiting lipid peroxidation. 

Specific Podocyte Protection: Curcumin demonstrates particular relevance for Nephrotic Syndrome secondary to Diabetic Nephropathy (DN). In models of high glucose exposure, Curcumin treatment successfully protected podocytes from injury. The mechanism involves suppressing the abnormal generation of Reactive Oxygen Species (ROS) and inhibiting the expression of Receptor-Interacting Protein Kinase 3 (RIPK3), suggesting it can specifically counteract the cellular death and injury pathways induced by hyperglycemia in podocytes. 

Clinical Efficacy and Bioavailability Challenge

Clinical evidence, primarily focused on NS secondary to specific systemic diseases, shows that turmeric capsule supplementation can reduce proteinuria and systolic blood pressure in patients with DN and Lupus Nephritis. Furthermore, it has demonstrated a marked reduction in inflammatory markers such as TNF-\alpha and IL-6 in CKD patients. 

A major clinical hurdle for Curcumin is its intrinsically poor oral bioavailability. To achieve clinically relevant serum concentrations, Curcumin must be combined with enhancers. Co-administration with piperine (from black pepper) is a common strategy that has been shown to increase Curcumin's serum concentration dramatically, often by up to 2000%. Without such specialized formulations, the ingested compound may not reach therapeutic levels at the target kidney tissue. 

3.4 The Comparison: Astragalus vs. Curcumin

When evaluating clinical applicability, Astragalus membranaceus currently offers the most compelling, broad-based evidence, supported by systematic reviews demonstrating a consistent and quantifiable reduction in 24-hour proteinuria across various NS etiologies. Curcumin, while possessing arguably more specific and elegant molecular mechanisms, particularly for DN, has weaker overall generalized NS clinical trial data and is challenged by the absolute requirement for enhanced bioavailability formulations. 

The primary limitation on the clinical recommendation for both agents, however, shifts from efficacy to safety when considering their use alongside standard nephrology treatment.

 Ingredient Active Compound Mechanism of Action in NS Observed Clinical Effect (Adjunctive) Safety Profile/Dosing Note
Astragalus (A. membranaceus) Polysaccharides (APS), Saponins Immunomodulatory; Inhibits NF-B mediated inflammation; Reduces cytokine release (IL-6, TNF-). Significant reduction in 24h proteinuria; Increase in serum albumin. Reduction in URTI incidence. Potential for immune-system activation, posing a critical risk when combined with immunosuppressants.
Curcumin (C. longa) Curcuminoids (Diferuloylmethane) Potent antioxidant, anti-inflammatory; Protects podocytes (RIPK3 suppression); Nrf2 activation. Reduction in inflammatory markers (TNF-, IL-6); Reduced proteinuria (especially DN, Lupus NS). Poor bioavailability (requires specific formulation/piperine). High doses can be toxic in transplant recipients.
Tripterygium wilfordii Polyglycosides (Triptolide) Immunosuppressive; Anti-inflammatory. Improved remission rate; Significant reduction in proteinuria. High inherent risk of toxicity: Severe hepatotoxicity and nephrotoxicity. Not suitable for general holistic recommendation.

Table 2: Comparative Efficacy and Mechanisms of Leading Phyto-Therapies in NS

IV. Evaluation of Other Complementary Ingredients

4.1 High-Risk, High-Efficacy Agents: Tripterygium wilfordii

Tripterygium wilfordii polyglycoside (TWP), another recognized TCM agent, possesses significant immunosuppressive properties, making it highly effective for treating autoimmune and inflammatory renal disorders, such as IgA nephropathy. Systematic reviews confirm that TWP can improve remission rates and reduce proteinuria significantly. 

However, the high potency of TWP is intrinsically linked to substantial safety concerns. The literature explicitly notes a persistent risk of multi-organ toxicity, including severe hepatotoxicity and nephrotoxicity. The magnitude of this safety risk mandates stringent medical supervision and rules it out as a safe, generally recommended holistic ingredient. Its use is limited to highly controlled, specialized contexts where its potent benefits outweigh the considerable risk of adverse effects. 

4.2 Nutritional and Metabolic Adjuncts

Omega-3 Polyunsaturated Fatty Acids (PUFAs)

Omega-3 fatty acids, particularly EPA and DHA derived from fatty fish, are valued for their role as precursors for eicosanoids that modify inflammatory processes, offering cardiovascular and anti-inflammatory protection. 

In proteinuria management, clinical evidence is inconclusive. While one review found no significant difference in proteinuria reduction when Omega-3 was combined with RAS inhibitors, other reports suggest a substantial reduction in proteinuria in specific glomerulopathies, such as IgA Nephropathy (IgAN). Although considered a safe dietary adjunct, the current scientific basis for widely recommending Omega-3 PUFAs as a powerful, general proteinuria reducer in NS remains weak. 

Probiotics

Probiotics, utilized for their role in modulating the gut-kidney axis, offer systemic support in CKD. Renal failure frequently compromises the gut barrier integrity. Probiotics help restore this barrier and reduce the production and absorption of uremic toxins (e.g., p-cresol) that contribute to systemic inflammation and renal damage. By lowering pro-inflammatory cytokine levels (TNF-\alpha, IL-6) and improving metabolic profiles, probiotics serve as an important supportive therapy. Their primary function is metabolic waste management and systemic anti-inflammation, complementing the conventional therapy, but they are not positioned as direct competitors to agents that directly modulate glomerular permeability. 

V. Safety Profile, Risk Mitigation, and Clinical Integration

The consideration of any plant-derived compound in Nephrotic Syndrome patients must be dominated by safety concerns, given the potential for severe, even life-threatening, interactions with high-risk conventional medications. The lack of FDA regulation regarding the dosage, content, and purity of herbal supplements places a significant burden on clinical oversight. 

5.1 Mandatory Disclosure: Potent Herb-Drug Interactions

The most immediate danger stems from agents that interfere with the metabolic clearance of immunosuppressants or directly antagonize their function.

The Immunomodulation Conflict (Astragalus)

Astragalus is explicitly documented to increase the activity of the immune system. This inherent immunomodulatory effect creates a critical pharmacological conflict when the herb is co-administered with immunosuppressive drugs, such as Cyclosporine or Cyclophosphamide, which aim to decrease immune activity. The potential consequence is a direct reduction in the efficacy of the immunosuppressive agent, which may precipitate disease relapse or, in transplant recipients, lead to acute graft rejection. This counteractive effect mandates that Astragalus be avoided in patients receiving potent immunosuppression unless strict clinical approval dictates otherwise. 

Metabolic Overload and Toxicity (Curcumin/Tacrolimus)

Curcumin’s interaction with the liver's Cytochrome P450 (CYP) enzyme system poses a severe hazard to patients receiving Calcineurin Inhibitors (CNIs). Tacrolimus, frequently used in refractory NS and post-transplantation, relies on CYP3A4 for clearance. High doses of turmeric/curcumin can inhibit this enzyme, preventing the drug from being cleared effectively. A documented case reported high-dose turmeric consumption causing a toxic accumulation of Tacrolimus, leading to acute renal failure in a kidney transplant recipient. This example demonstrates how even therapeutically promising natural agents can become profoundly nephrotoxic when they disrupt the delicate pharmacokinetics of critical, narrow-therapeutic-index drugs. 

Other Critical Drug Interactions

Other herbal agents carry similar, well-known risks. St. John’s Wort (Hypericum perforatum) is strictly contraindicated with immunosuppressants like Cyclosporine because it induces CYP3A4 metabolism, accelerating drug clearance and leading to dangerously subtherapeutic drug levels that can cause graft rejection. Licorice Root (Glycyrrhiza glabra) should be avoided in NS patients on diuretics or RAS inhibitors because its mineralocorticoid-like properties cause sodium and fluid retention, directly counteracting the edema management strategy and exacerbating hypertension.

 Herbal Agent Conventional Drug Class Affected Specific Drug Examples Mechanism of Interaction Clinical Risk in NS Patients
Astragalus (A. membranaceus) Immunosuppressants Cyclosporine, Tacrolimus, Prednisone Enhances immune function (counteractive immunomodulation). Decreased effectiveness of immunosuppressants; Risk of disease relapse or graft rejection.
Turmeric/Curcumin (High Dose) Immunosuppressants Tacrolimus (CNIs) Inhibition of CYP3A4-mediated liver clearance. Increased Tacrolimus concentration to toxic levels; Risk of acute renal failure.
St. John's Wort (H. perforatum) Immunosuppressants Cyclosporine, Tacrolimus Induces CYP3A4 metabolism and P-glycoprotein. Subtherapeutic drug levels; Risk of acute graft rejection.
Licorice Root (G. glabra) Diuretics, RAS Inhibitors Furosemide, ACEi/ARB Mineralocorticoid effect (sodium/water retention). Counteracts edema treatment; Exacerbates hypertension.
Creatine Nephroprotective Status None (Exogenous Supplement) Increases renal load, especially with dehydration. Potential for rhabdomyolysis and acute kidney injury (AKI) in susceptible individuals.

 

5.2 Identifying and Avoiding Nephrotoxic Compounds

Patients must also avoid herbs that are inherently nephrotoxic or contribute to complications. High-phosphorus containing herbs, such as Nettle (Stinging Nettle), Horsetail, Alfalfa, and American Ginseng, must be limited in patients with advancing CKD stages who require phosphorus restriction. Exogenous compounds that increase renal workload, such as Creatine, can predispose susceptible individuals to acute kidney injury and should be avoided. Finally, herbs explicitly contraindicated due to inherent renal damage risk, such as Aristolochia products (birthwort, wild ginger), must never be consumed. 

VI. Synthesis and Recommendations

6.1 Identification of the Best Adjunctive Ingredient

Based on a stringent review of clinical data demonstrating measurable reductions in 24-hour proteinuria, the primary indicator of Nephrotic Syndrome severity, Astragalus membranaceus is scientifically supported as the most efficacious holistic ingredient for use as an adjunct to conventional therapy. Its proven ability to reduce protein loss and increase serum albumin is corroborated by mechanistic evidence showing suppression of inflammatory pathways (NF-\kappaB) and support for immune function. 

However, the therapeutic use of Astragalus must be carefully restricted. Because its mechanism involves immune activation, it poses a direct and life-threatening conflict with standard immunosuppressive agents (e.g., Cyclosporine, Tacrolimus, Cyclophosphamide). Therefore, Astragalus can only be recommended under the explicit guidance of a nephrology team, ideally reserved for steroid-sensitive patients or those managed without powerful immune-suppressing drugs. 

Curcumin represents the second-most promising candidate, particularly for secondary NS etiologies like Diabetic Nephropathy, given its highly specific protective action on podocytes against oxidative stress. The limitation of Curcumin is its complex formulation requirement (bioavailability) and its high risk of metabolic interaction with CNIs. 

6.2 Summary of Integration Guidelines

Any holistic intervention must be considered a strictly adjunctive measure, reinforcing the primary pharmacological management (steroids, RAS inhibitors). The ultimate integration guidelines prioritize safety above all:

Mandatory Clinical Oversight: All herbal or complementary supplements must be reviewed and approved by the patient’s nephrology team to screen for adverse effects, nephrotoxicity, and, most critically, potential drug-drug interactions, especially with immunosuppressants. 

Avoidance of Nephrotoxic Agents: Strict avoidance of all known nephrotoxic compounds (e.g., Aristolochia, high-phosphorus herbs) is required to prevent accelerated CKD progression. 

Quality and Purity: Use of only standardized extracts and products with third-party verification of content and purity is essential, mitigating the risk associated with poorly regulated supplements. 

Targeted Application: The choice between Astragalus and Curcumin should reflect the underlying etiology of the Nephrotic Syndrome, aligning the herb’s specific mechanism (immunomodulation vs. antioxidant podocyte protection) with the patient's specific pathology.

6.3 Future Research Directions

To translate the promising mechanistic and preliminary clinical data into broader acceptance, future efforts must focus on high-quality, large-scale, multi-center Randomized Controlled Trials (RCTs). These trials must address the safety profile and efficacy of both Astragalus and Curcumin when administered alongside specific modern immunosuppressive regimens, with particular attention paid to developing safe, bioavailable Curcumin formulations that avoid interference with the CYP450 system. Rigorous data is required to establish safe, evidence-based dosing schedules that integrate these phyto-therapies into contemporary nephrology practice without compromising patient safety.

 

Sources:

  • https://www.ncbi.nlm.nih.gov/books/NBK470444/?hl=en-US
  • https://www.kidneyfund.org/all-about-kidneys/other-kidney-problems/nephrotic-syndrome-symptoms-causes-and-treatment?hl=en-US
  • https://www.mayoclinic.org/diseases-conditions/nephrotic-syndrome/symptoms-causes/syc-20375608?hl=en-US
  • https://www.aafp.org/pubs/afp/issues/2016/0315/p479.html?hl=en-US
  • https://www.rch.org.au/clinicalguide/guideline_index/nephrotic_syndrome/?hl=en-US
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC4891386/?hl=en-US
  • https://www.kidneyfund.org/treatments/medicines-kidney-disease/herbal-supplements-and-chronic-kidney-disease-ckd?hl=en-US
  • https://pubmed.ncbi.nlm.nih.gov/11213066/
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC7547748/?hl=en-US
  • https://www.kidney.org/kidney-topics/herbal-supplements-and-kidney-disease?hl=en-US
  • https://www.pharmacytimes.com/view/5-natural-products-that-can-trigger-renal-failure?hl=en-US
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC3812398/?hl=en-US
  • https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.774414/full?hl=en-US
  • https://www.stanfordchildrens.org/en/topic/default?id=nutrition-and-nephrotic-syndrome-90-P03099&hl=en-US
  • https://childrenswi.org/medical-care/nephrology/conditions/nephrotic-syndrome/nutrition-and-nephrotic-syndrome?hl=en-US
  • https://nephcure.org/managing-rkd/diet-and-nutrition/?hl=en-US
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC4214538/?hl=en-US
  • https://pubmed.ncbi.nlm.nih.gov/8804233/
  • https://www.mdpi.com/1422-0067/24/1/44
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC3812398/
  • https://tcimr.org.sg/astragalus-membranaceus-usage-in-nephrotic-syndrome/
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC10589061/
  • https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008369.pub2/full
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC3638577/
  • https://pubmed.ncbi.nlm.nih.gov/17161813/
  • https://www.researchgate.net/publication/363830558_Research_on_Mechanism_of_Curcumin_with_Chitosan_Nanoparticles_in_Regulating_the_Activity_of_Podocytes_in_Diabetic_Nephropathy_Through_Alleviating_Oxidative_Stress_and_Inflammation
  • https://www.jrenendo.com/PDF/jre-8-e23063.pdf
  • https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00912/full
  • https://www.researchgate.net/publication/385084106_Curcuma_longa_L_turmeric_as_adjuvant_therapy_in_childhood_idiopathic_nephrotic_syndrome_a_double-blind_randomized_placebo-controlled_clinical_trial
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC9189280/
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC6271001/
  • https://www.mdpi.com/2072-6643/15/10/2239
  • https://www.merckmanuals.com/home/special-subjects/dietary-supplements-and-vitamins/astragalus
  • https://www.webmd.com/vitamins/ai/ingredientmono-963/astragalus
  • https://www.pharmacytimes.com/view/5-natural-products-that-can-trigger-renal-failure
  • https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.774414/full
  • https://www.europeanreview.org/wp/wp-content/uploads/8756-8770.pdf
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC11150713/
  • https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1282610/full
  • https://www.europeanreview.org/article/30547
  • https://www.ncbi.nlm.nih.gov/books/NBK350635/
  • https://www.ncbi.nlm.nih.gov/books/NBK350638/
  • https://www.tandfonline.com/doi/full/10.2147/IJNRD.S237527
  • https://www.mdpi.com/1422-0067/25/19/10429
  • https://www.organscigroup.us/articles/ARDM-8-144.php
  • https://www.kidneyfund.org/treatments/medicines-kidney-disease/herbal-supplements-and-chronic-kidney-disease-ckd
  • https://www.kidney.org/kidney-topics/herbal-supplements-and-kidney-disease
  • https://pubmed.ncbi.nlm.nih.gov/11213066/
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC7547748/
Back to blog